Aprea Therapeutics, Inc. APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition
Aprea Therapeutics, Inc. (APRE) reported APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition of $2.60 million for the 12-month period ending 2022-12-31, per its 10-K filed 2024-03-26.
Discontinued › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition · last filed 2024-03-26
- Aprea Therapeutics, Inc. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2022-06-30 was $2.60M.
- Aprea Therapeutics, Inc. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2022 was $2.60M.
| Period end | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 12 month |
|---|---|---|
| 2022-12-31 | $2.60M 10-K · filed 2024-03-26 | |
| 2022-06-30 | $2.60M 10-Q · filed 2023-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |